Daniel Chinnapen

Daniel Chinnapen has an extensive work experience in the field of scientific research and development. Daniel is currently the Head of Targeted Delivery at Laronde since October 2021. Prior to that, they served as a member of the Scientific Advisory Board at Transcera from December 2021 to May 2022. From December 2019 to October 2021, Daniel held the position of Chief Scientific Officer at Vantage Hemp Co.

Before joining the industry, Daniel worked at Harvard Medical School, where they were an Assistant Professor of Pediatrics from January 2016 to October 2021. During their time at Harvard, they led a research lab focused on developing novel delivery technology for small secreted peptides and investigating lipid trafficking mechanisms. Daniel also worked as an Instructor of Pediatrics from January 2013 to January 2016 at Harvard Medical School, where they contributed to the development of therapeutic peptides for metabolic diseases and enhanced enzyme replacement therapy for lysosomal storage diseases.

Daniel also gained valuable experience as a Staff Scientist at Boston Children's Hospital from January 2016 to December 2019, where they focused on lipid-based delivery for rare lysosomal diseases and enzyme replacement therapy.

Before their academic positions, Daniel worked as a Senior Scientist in Cell Biology/Delivery at Permeon Biologics and later as a Senior Scientist in Platform Biology at Anchor Therapeutics. Daniel began their career as a Postdoctoral Fellow at Children's Hospital Boston/Harvard Medical School from January 2006 to September 2010, followed by a Postdoctoral Fellowship at MIT from 2005 to 2006.

Overall, Daniel Chinnapen's work experience showcases their expertise in targeted drug delivery, scientific research, and the development of novel therapeutic approaches.

Daniel Chinnapen began their educational journey by obtaining a Bachelor of Science degree in Biochemistry from Simon Fraser University. Afterward, they pursued a Ph.D. in Molecular Biology and Biochemistry from the same institution. Following their Ph.D., Daniel furthered their education by completing Postdoctoral studies at the Massachusetts Institute of Technology, focusing on RNA SELEX and protein engineering. Daniel then went on to complete another Postdoctoral program at Harvard Medical School, concentrating on Lipid Trafficking.